The APP/PS1 double transgenic mouse model, also known as APPswe/PS1ΔE9 or simply APP/PS1, is one of the most widely used animal models for studying Alzheimer's disease amyloid pathology. This model co-exembles mutant forms of the amyloid precursor protein (APP) with mutant presenilin 1 (PS1), leading to accelerated amyloid-beta (Aβ) deposition in the brain [1].
The APP/PS1 double transgenic model exists in two main variants distinguished by their PS1 mutation: PS1ΔE9 (exon 9 deletion) and PS1 M146L (point mutation). Both variants are widely used in AD research with similar amyloid phenotypes but distinct genetic mechanisms.
The APPswe mutation (Swedish) involves a double mutation (K670N/M671L) at the APP cleavage site:
The PS1ΔE9 mutation is a deletion of exon 9 in the presenilin 1 gene:
The PS1 M146L mutation is a point mutation replacing methionine with leucine at position 146:
The APP/PS1-M146L model uses the same APPswe mutation but pairs it with the M146L point mutation instead of the ΔE9 deletion. Both models produce robust amyloid pathology, but the M146L variant represents a more subtle genetic alteration while still accelerating Aβ42 production.
| Feature | APP/PS1ΔE9 | APP/PS1-M146L |
|---|---|---|
| PS1 mutation | Exon 9 deletion | M146L point mutation |
| Genetic mechanism | Large genomic deletion | Single amino acid substitution |
| Aβ42/Aβ40 increase | ~5-10 fold | ~2-3 fold |
| Plaque onset | 6 months | 5-8 months |
| Phenotype severity | Moderate-severe | Moderate |
| Research use | Most common | Less common |
The model uses:
APP/PS1 mice develop robust amyloid pathology:
The model produces multiple Aβ species:
Beyond amyloid, these mice show:
APP/PS1 mice exhibit:
The model also shows:
APP/PS1 mice are used to test:
The model enables investigation of:
| Model | APP Mutation | PS Mutation | Plaque Onset | Key Features |
|---|---|---|---|---|
| APP/PS1ΔE9 | Swedish | ΔE9 | 6 months | High Aβ42, robust plaques |
| APP/PS1-M146L | Swedish | M146L | 5-8 months | High Aβ42, moderate plaques |
| 3xTg | Swedish + London | ΔE9 | 6-12 months | Both amyloid and tau |
| 5xFAD | 3 APP + 2 PS1 | M146L + L286V | 2 months | Very rapid, severe |
| Tg2576 | Swedish | None | 9-12 months | Slower, pure amyloid |
APP/PS1 mice show characteristic changes in cerebrospinal fluid biomarkers that mirror patterns observed in human AD[15]:
The temporal dynamics of these biomarkers provide insights into disease staging and therapeutic response monitoring. Studies using longitudinal CSF sampling demonstrate that biomarker changes precede behavioral deficits, enabling early intervention studies[15:1].
Recent advances have enabled detection of AD biomarkers in mouse plasma[16]:
These blood-based biomarkers offer minimally invasive approaches for monitoring disease progression and therapeutic efficacy in preclinical studies.
APP/PS1 mice exhibit progressive brain metabolic deficits[17]:
FDG-PET imaging in APP/PS1 mice reveals regional patterns of hypometabolism that correlate with amyloid deposition and cognitive impairment. These metabolic changes provide targets for metabolic interventions.
Beyond CNS changes, APP/PS1 mice show systemic metabolic alterations:
Understanding these systemic metabolic changes informs comprehensive therapeutic approaches targeting whole-body physiology.
APP/PS1 mice exhibit profound synaptic circuit alterations beyond individual synapse loss[18]:
These network-level changes explain the cognitive deficits that exceed what would be predicted from synaptic marker loss alone. Restoring network function represents a therapeutic target distinct from amyloid clearance.
Specific neural circuits show differential vulnerability in APP/PS1 mice:
Understanding circuit-specific vulnerabilities enables targeted interventions that address the earliest functional deficits.
Despite robust efficacy in APP/PS1 models, many therapeutic approaches fail in human trials[19]:
These translation challenges highlight the need for improved model systems and better clinical trial design.
Given the multifactorial nature of AD, combination approaches show promise:
APP/PS1 models provide a platform for testing combination approaches that may improve translation to human trials.
In vivo two-photon imaging enables visualization of dynamic processes in APP/PS1 mice[20]:
These imaging approaches reveal processes invisible in endpoint histology and enable time-course studies within individual animals.
Advanced PET tracers allow molecular characterization in living mice:
Correlating PET signals with histopathology validates imaging biomarkers for preclinical therapeutic screening.
Jankord R, et al. Neurobiology of Aging. 2009;30(7):1097-1108. 2009. ↩︎
Moechars D, et al. Journal of Neuroscience. 1999;19(14):5782-5791. 1999. ↩︎
Borchelt DR, et al. Neuron. 1996;17(5):1005-1013. 1996. ↩︎
Radde R, et al. EMBO Reports. 2006;7(9):940-946. 2006. ↩︎
Garcia-Alloza M, et al. Neurobiology of Aging. 2006;27(11):1632-1643. 2006. ↩︎
Wirths O, et al. Brain Research Reviews. 2009;59(2):313-320. 2009. ↩︎
Heneka MT, et al. Neurobiology of Disease. 2013;52:121-131. 2013. ↩︎
Morgan D, et al. Neurobiology of Learning and Memory. 2000;74(1):65-71. 2000. ↩︎
Shen J, et al. Neurobiology of Disease. 2002;10(3):324-334. 2002. ↩︎
Van Dooren T, et al. Journal of Alzheimer's Disease. 2006;9(3):255-264. 2006. ↩︎
Schenk D, et al. Nature. 1999;400(6740):173-177. 1999. ↩︎
Cai D, et al. Neuron. 2012;74(3):393-404. 2012. ↩︎
Oddo S, et al. Brain Research Reviews. 2006;52(1):80-98. 2006. ↩︎
Kelley AR, et al. Acta Neuropathologica Communications. 2019;7(1):31. 2019. ↩︎
Liu Y, et al. Nature Communications. 2023;14(1):2789. 2023. ↩︎ ↩︎
Mastrogiovanni M, et al. Aging Cell. 2022;21(1):e13547. 2022. ↩︎
Zhang Y, et al. Journal of Alzheimer's Disease. 2023;91(1):299-314. 2023. ↩︎
Forrest CM, et al. Brain Pathology. 2024;34(2):e13234. 2024. ↩︎
Deutsch GH, et al. Acta Neuropathologica. 2024;147(1):45. 2024. ↩︎
Rosen RF, et al. Neurobiology of Aging. 2023;127:45-55. 2023. ↩︎